Review Article on Neoadjuvant Therapy for Ovarian Cancer
Pathological response of ovarian cancer to neoadjuvant chemotherapy
Abstract
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer
(OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized
by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple
reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations
of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy
Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental
masses. CRS3 (complete or near-complete response) is characterized by the lack of residual tumor cells in the
omentum or presence of tumor foci up to 2 mm maximum size. It is observed after NACT in approximately
30-40% patients with high-grade serous
(OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized
by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple
reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations
of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy
Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental
masses. CRS3 (complete or near-complete response) is characterized by the lack of residual tumor cells in the
omentum or presence of tumor foci up to 2 mm maximum size. It is observed after NACT in approximately
30-40% patients with high-grade serous
